Communicable Diseases Intelligence, Volume 21, Issue number 21 - 30 October 1997
Meningococcal disease in New South Wales
This article published in Communicable Diseases Intelligence Volume 21, Issue number 21, contains two cases of outbreaks of meningococcal disease serogroup C.
Communicable Diseases Intelligence subscriptions
Sign-up to email updates: Subscribe Now
Communicable Diseases Surveillance
Communicable Diseases Intelligence
A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.
In early October two separate outbreaks of meningococcal disease (serogroup C) were reported to the New South Wales Health Department. The first of these involved two university students who had attended the same intervarsity sporting event in New South Wales. One student, from Western Australia, died. In the second outbreak three cases were reported at a high school.
It is usual to observe an increase in the number of reports of meningococcal disease at this time of year.1 Meningococcal meningitis is caused by the bacterium, Neisseria meningitidis. This organism is common in the community and exists harmlessly in the throats of many adults and children. It is spread by respiratory droplets from the nose and throat of an infected person. In a small proportion of individuals infection progresses to an acute invasive disease. Symptoms include high temperature, fever, sore neck, headache, vomiting, rash and joint pain. Treatment is successful in the majority of cases if administered promptly. In cases of suspected meningococcal disease benzylpenicillin is the drug of choice. Where other causes of bacterial meningitis could be involved ceftriaxone should be used where available.2
The National Health and Medical Research Council recommends rifampicin chemoprophylaxis for contacts of a case of invasive meningococcal infection.2,3 Vaccination is only recommended in special circumstances. Most cases of disease in Australia are due to serogroup B, for which no effective vaccine is available.3,4 In the case of an outbreak due to a vaccine preventable serogroup the National Health and Medical Research Council recommends that a vaccination program should be considered if the population at risk can be clearly identified, such as in a day-care centre, school or university. Routine vaccination is not recommended as the risk of meningococcal disease in Australia is low.
1. Curran M, Harvey B, Crerar S et al. Australia's notifiable diseases status, 1996. Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 1997;21:296.
2. National Health and Medical Research Council. Guidelines for the control of meningococcal disease in Australia. Canberra: Australian Government Publishing Service, 1997.
3. National Health and Medical Research Council. The Australian immunisation handbook. Sixth edition. Canberra: Australian Government Publishing Service, 1996.
4. Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme 1996. Commun Dis Intell 1997;21:217-221.
This article was published in Communicable Diseases Intelligence Vol 21 No 21, October 1997.